Related Experiment Video

Updated: Aug 29, 2026

Generation and Functional Verification of Hypoxia-Sensitive Chimeric Antigen Receptor-T Cells
09:12

Generation and Functional Verification of Hypoxia-Sensitive Chimeric Antigen Receptor-T Cells

Published on: June 14, 2024

Antiangiogenic hypoxic cytotoxin TX-402 inhibits hypoxia-inducible factor 1 signaling pathway

Hideko Nagasawa1, Naoko Mikamo, Yoshimi Nakajima

  • 1Department of Biological Science and Technology, Faculty of Engineering, University of Tokushima, Minimijosanjimacho-2, Tokushima 770-8506, Japan.

Anticancer Research
|December 12, 2003
PubMed
Abstract

Insights

Hypoxic cytotoxins like TX-402 show potent anti-cancer effects by inhibiting tumor cell growth and angiogenesis. These compounds suppress key hypoxia-induced genes, offering a new strategy for targeted cancer therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Hypoxia is a key target in cancer therapy.
  • Hypoxic cytotoxins induce p53-independent apoptosis and inhibit angiogenesis.
  • TX-1102, tirapazamine (TPZ), and TX-402 are examples of these agents.

Purpose of the Study:

  • To investigate the effects of antiangiogenic hypoxic cytotoxins on hypoxia-induced gene expression.
  • To evaluate hypoxia-selective cytotoxicity of these agents in cancer cells.
  • To assess the impact on p53 status.

Main Methods:

  • Utilized human squamous cell carcinoma (SAS) and p53-deficient H1299 cells.
  • Assessed cytotoxicity and gene expression under hypoxic conditions.
  • Employed chick embryo chorioallantoic membrane (CAM) assay for angiogenesis inhibition.
  • RT-PCR analysis for gene expression (VEGF, GLUT-3, HIF-1 alpha).

Main Results:

  • TX-402 demonstrated superior hypoxia-selective cytotoxicity compared to TPZ, irrespective of p53 status.
  • All tested compounds potently inhibited angiogenesis.
  • TX-402 selectively reduced hypoxia-induced VEGF and GLUT-3 expression.
  • TX-402 suppressed both mRNA and protein expression of HIF-1 alpha.

Conclusions:

  • The antiangiogenic effects of hypoxic cytotoxins stem from suppressing VEGF and HIF-1 induction.
  • Hypoxic cytotoxins function as HIF-1 inhibitors.
  • These findings support their use in hypoxia-targeted cancer therapy to improve treatment outcomes.

More Related Videos

Induction and Testing of Hypoxia in Cell Culture07:01

Induction and Testing of Hypoxia in Cell Culture

Published on: August 12, 2011

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.